Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI

被引:5
作者
Woo, Sungmin [1 ,2 ]
Becker, Anton S. [1 ,2 ]
Das, Jeeban P. [1 ]
Ghafoor, Soleen [3 ]
Arita, Yuki [1 ]
Benfante, Nicole [4 ]
Gangai, Natalie [1 ]
Teo, Min Yuen [5 ]
Goh, Alvin C. [4 ]
Vargas, Hebert A. [1 ,2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10065 USA
[2] NYU Langone Hlth, Dept Radiol, 660 1st Ave, New York, NY 10016 USA
[3] Univ Hosp Zurich, Inst Diagnost & Intervent Radiol, Ramistr 100, CH-8091 Zurich, Switzerland
[4] Mem Sloan Kettering Canc Ctr, Dept Surg, Urol Serv, 1275 York Ave, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, New York, NY 10065 USA
关键词
Biparametric; Cystectomy; Magnetic resonance imaging; Muscle-invasive bladder cancer; Multiparametric; Neoadjuvant chemotherapy; Prognosis; Survival; Urothelial; Response assessment; CONTRAST-ENHANCED MRI; THERAPEUTIC RESPONSE; CELL CARCINOMA; DATA SYSTEM; CYSTECTOMY; CHEMORADIOTHERAPY; METHOTREXATE; VINBLASTINE; CISPLATIN; SURVIVAL;
D O I
10.1186/s40644-023-00632-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNeoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC). Response assessment after NAC is important but suboptimal using CT. We assessed MRI without vs. with intravenous contrast (biparametric [BP] vs. multiparametric [MP]) for identifying residual disease on cystectomy and explored its prognostic role.MethodsConsecutive MIBC patients that underwent NAC, MRI, and cystectomy between January 2000-November 2022 were identified. Two radiologists reviewed BP-MRI (T2 + DWI) and MP-MRI (T2 + DWI + DCE) for residual tumor. Diagnostic performances were compared using receiver operating characteristic curve analysis. Kaplan-Meier curves and Cox proportional-hazards models were used to evaluate association with disease-free survival (DFS).Results61 patients (36 men and 25 women; median age 65 years, interquartile range 59-72) were included. After NAC, no residual disease was detected on pathology in 19 (31.1%) patients. BP-MRI was more accurate than MP-MRI for detecting residual disease after NAC: area under the curve = 0.75 (95% confidence interval (CI), 0.62-0.85) vs. 0.58 (95% CI, 0.45-0.70; p = 0.043). Sensitivity were identical (65.1%; 95% CI, 49.1-79.0) but specificity was higher in BP-MRI compared with MP-MRI for determining residual disease: 77.8% (95% CI, 52.4-93.6) vs. 38.9% (95% CI, 17.3-64.3), respectively. Positive BP-MRI and residual disease on pathology were both associated with worse DFS: hazard ratio (HR) = 4.01 (95% CI, 1.70-9.46; p = 0.002) and HR = 5.13 (95% CI, 2.66-17.13; p = 0.008), respectively. Concordance between MRI and pathology results was significantly associated with DFS. Concordant positive (MRI+/pathology+) patients showed worse DFS than concordant negative (MRI-/pathology-) patients (HR = 8.75, 95% CI, 2.02-37.82; p = 0.004) and compared to the discordant group (MRI+/pathology- or MRI-/pathology+) with HR = 3.48 (95% CI, 1.39-8.71; p = 0.014).ConclusionBP-MRI was more accurate than MP-MRI for identifying residual disease after NAC. A negative BP-MRI was associated with better outcomes, providing complementary information to pathological assessment of cystectomy specimens.
引用
收藏
页数:11
相关论文
共 50 条
[31]   Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report [J].
Robert Rosenblatt ;
Markus Johansson ;
Farhood Alamdari ;
Alexander Sidiki ;
Benny Holmström ;
Johan Hansson ;
Janos Vasko ;
Per Marits ;
Susanne Gabrielsson ;
Katrine Riklund ;
Ola Winqvist ;
Amir Sherif .
World Journal of Urology, 2017, 35 :921-927
[32]   Survival outcomes of patients diagnosed with muscle-invasive bladder cancer who showed a response after neoadjuvant chemotherapy and refused radical cystectomy, and patients who had radical cystectomy or received chemoradiotherapy [J].
Tunc, Sezai ;
Urakci, Zuhat ;
Ebinc, Senar ;
Ileri, Serdar ;
Kalkan, Ziya ;
Oruc, Zeynep ;
Kucukoner, Mehmet ;
Kaplan, Muhammet Ali ;
Isikdogan, Abdurrahman .
ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (05) :331-338
[33]   Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer [J].
Khaki, Ali Raza ;
Shan, Yong ;
Nelson, Richard E. ;
Kaul, Sapna ;
Gore, John L. ;
Grivas, Petros ;
Williams, Stephen B. .
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2021, 39 (10) :732.e9-732.e16
[34]   Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314 NCT02177695) ; [J].
Flaig, Thomas W. ;
Tangen, Catherine M. ;
Daneshmand, Siamak ;
Alva, Ajjai Shivaram ;
Lucia, M. Scott ;
McConkey, David James ;
Theodorescu, Dan ;
Goldkorn, Amir ;
Milowsky, Matthew I. ;
Bangs, Rick ;
MacVicar, Gary R. ;
Bastos, Bruno R. ;
Fowles, Jared S. ;
Gustafson, Daniel L. ;
Plets, Melissa ;
Thompson Jr, Ian M. ;
Lerner, Seth P. .
EUROPEAN UROLOGY, 2023, 84 (03) :341-347
[35]   Comparative Effectiveness of Neoadjuvant Pembrolizumab Versus Cisplatin-based Chemotherapy or Upfront Radical Cystectomy in Patients with Muscle-invasive Urothelial Bladder Cancer [J].
Li, Roger ;
Nocera, Luigi ;
Rose, Kyle M. ;
Raggi, Daniele ;
Naidu, Shreyas ;
Mercinelli, Chiara ;
Cigliola, Antonio ;
Tateo, Valentina ;
Patane, Damiano ;
Grass, G. Daniel ;
Gilbert, Scott M. ;
Sexton, Wade J. ;
Bandini, Marco ;
Moschini, Marco ;
Briganti, Alberto ;
Montorsi, Francesco ;
Spiess, Philippe E. ;
Necchi, Andrea .
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03) :614-624
[36]   [15O]H2O PET/MRI for Assessment of Complete Response to Neoadjuvant or Induction Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Pilot Study [J].
Korner, Stefanie Korsgaard ;
Tolbod, Lars Poulsen ;
Pedersen, Bodil G. ;
Boellaard, Thierry ;
Milling, Rikke Vilsboll ;
Brandt, Simone Buchardt ;
Agerbaek, Mads ;
Dyrskjot, Lars ;
Bouchelouche, Kirsten ;
Jensen, Jorgen B. .
JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
[37]   Impact of Variant Histology on Occult Nodal Metastasis after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Review of the National Cancer Database [J].
Fu, Melinda ;
Klose, Charles ;
Sparks, Andrew ;
Whalen, Michael .
CLINICAL GENITOURINARY CANCER, 2022, 20 (02) :E135-E139
[38]   Are We Moving Closer to Accurate Restaging after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer? [J].
Packiam, Vignesh T. ;
Bhindi, Bimal .
EUROPEAN UROLOGY, 2021, 79 (03) :372-373
[39]   Pathological response and survival outcomes after neoadjuvant chemotherapy with radical cystectomy in octogenarians for muscle-invasive bladder cancer: an observational database study [J].
Avudaiappan, Arjun Pon ;
Prabhakar, Pushan ;
Sandman, Mayer Simcha ;
Rubens, Muni ;
Garje, Rohan ;
Eldefrawy, Ahmed ;
Manoharan, Murugesan .
BMC UROLOGY, 2024, 24 (01)
[40]   Development of a MRI-Based Radiomics Nomogram for Prediction of Response of Patients With Muscle-Invasive Bladder Cancer to Neoadjuvant Chemotherapy [J].
Zhang, Xinxin ;
Wang, Yichen ;
Zhang, Jin ;
Zhang, Lianyu ;
Wang, Sicong ;
Chen, Yan .
FRONTIERS IN ONCOLOGY, 2022, 12